Recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma

  • Group for the Respect of Ethics and Excellence in Science (GREES): Asthma section
  • S. T. Holgate
  • J. Bousquet
  • K. F. Chung
  • H. Bisgaard
  • R. Pauwels
  • L. Fabbri
  • K. Rabe
  • M. Doherty
  • N. J. C. Snell
  • F. Cuss
  • M. D’Amato
  • J. Y. Reginster
Original Article


asthma therapy clinical trials drug registration 


  1. 1.
    Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105:193–204.PubMedCrossRefGoogle Scholar
  2. 2.
    Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000; 161:1720–1745.PubMedGoogle Scholar
  3. 3.
    Global Initiative for Asthma. Global strategy for asthma management and prevention. National Institutes of Health, National Heart, Lung, and Blood Institute.
  4. 4.
    Martinez FD. Links between pediatric and adult asthma. J Allergy Clin Immunol 2001; 107:S449–S455.PubMedCrossRefGoogle Scholar
  5. 5.
    Postma DS, Gerritsen J, Holgate ST. The link between asthma and COPD. Foreword, summary and conclusions. Clin Exp Allergy 1999; 29 (suppl 2):2–7.PubMedGoogle Scholar
  6. 6.
    Recommendations for the registration of drugs used in the treatment of osteoarthritis. Group for the respect of ethics and excellence in science (GREES): osteoarthritis section. Ann Rheum Dis 1996; 55:552–557.CrossRefGoogle Scholar
  7. 7.
    Leong KP, Huston DP. Understanding the pathogenesis of allergic asthma using mouse models. Ann Allergy Asthma Immunol 2001; 87:96–109.PubMedCrossRefGoogle Scholar
  8. 8.
    American Thoracic Society. Lung function testing: selection of reference values and interpretative strategies. Am Rev Respir Dis 1991; 144:1202–1289.CrossRefGoogle Scholar
  9. 9.
    Reddel H, Ware S, Marks G, Salome C, Jenkins C, Woolcock A. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353:364–369 (published erratum appears in Lancet 1999; 353:758).PubMedCrossRefGoogle Scholar
  10. 10.
    Stirling RG, Chung KF. Severe asthma: definition and mechanisms. Allergy 2001; 56:825–840.PubMedCrossRefGoogle Scholar
  11. 11.
    Gibson PG, Wong BJ, Hepperle MJ, Kline PA, Girgis-Gabardo A, Guyatt G, et al. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 1992; 22:525–532.PubMedCrossRefGoogle Scholar
  12. 12.
    Tattersfield AE, Postma DS, Barnes PJ, Svensson K, Bauer CA, O’Byrne PM, et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999; 160:594–599.PubMedGoogle Scholar
  13. 13.
    Cockcroft DW, Swystun VA. Asthma control versus asthma severity. J Allergy Clin Immunol 1996; 98:1016–1018.PubMedCrossRefGoogle Scholar
  14. 14.
    Hargreave FE, Sterk P, Adelroth EC, Ramsdale EH, O’Byrne PM. Airway responsiveness to histamine or methacholine: advances in measurement and interpretation. Respiration 1986; 2:72–76.CrossRefGoogle Scholar
  15. 15.
    Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O’Byrne PM, Anderson SD, et al. Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16 (suppl):53–83.Google Scholar
  16. 16.
    Cockcroft DW. Airway responses to inhaled allergens. Can Respir J 1998; 5 (suppl A):14A–17A.PubMedGoogle Scholar
  17. 17.
    Arshad SH. Bronchial allergen challenge: a model for chronic allergic asthma? Clin Exp Allergy 2000; 30:12–15.PubMedCrossRefGoogle Scholar
  18. 18.
    Ihre E, Axelsson IG, Zetterstrom O. Late asthmatic reactions and bronchial variability after challenge with low doses of allergen. Clin Allergy 1988; 18:557–567.PubMedCrossRefGoogle Scholar
  19. 19.
    Bousquet J, Van-Cauwenberge P, Khaltaev N. (chairmen). Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001; 108 (suppl):S1–S325.Google Scholar
  20. 20.
    Van Schoor J, Joos GF, Pauwels RA. Indirect bronchial hyperresponsiveness in asthma: mechanisms, pharmacology and implications for clinical research. Eur Respir J 2000; 16:514–533.PubMedCrossRefGoogle Scholar
  21. 21.
    Crimi E, Spanevello A, Neri M, Ind PW, Rossi GA, Brusasco V. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998; 157:4–9.PubMedGoogle Scholar
  22. 22.
    Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. Br Med J 2001; 323:253–256.CrossRefGoogle Scholar
  23. 23.
    Ciba Guest Symposium. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. Thorax 1959; 14:286–299.CrossRefGoogle Scholar
  24. 24.
    Stahl E. Correlation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respir Med 2000; 94:735–741.PubMedCrossRefGoogle Scholar
  25. 25.
    Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial? Eur Respir J 1999; 14:23–27.PubMedCrossRefGoogle Scholar
  26. 26.
    Hyde JS, Koch DF, Isenberg PD, Werner P. Technetium Tc99m macroaggregated albumin lung scans. Use in chronic childhood asthma. JAMA 1976; 235:1125–1130.PubMedCrossRefGoogle Scholar
  27. 27.
    Juniper EF, O’Byrne PM, Ferrie PJ, King DR, Roberts JN. Measuring asthma control. Clinic questionnaire or daily diary? Am J Respir Crit Care Med 2000; 162:1330–1334.PubMedGoogle Scholar
  28. 28.
    Bateman ED, Bousquet J, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001; 17:589–595.PubMedCrossRefGoogle Scholar
  29. 29.
    Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337:1405–1411.PubMedCrossRefGoogle Scholar
  30. 30.
    Ware Jr JE, Kemp JP, Buchner DA, Singer AE, Nolop KB, Goss TF. The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults. Qual Life Res 1998; 7:235–244.PubMedCrossRefGoogle Scholar
  31. 31.
    Rutten-van-Molken MP, Custers F, van-Doorslaer EK, Jansen CC, Heurman L, Maesen FP, et al. Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life. Eur Respir J 1995; 8:888–898.PubMedGoogle Scholar
  32. 32.
    Juniper EF. Quality of life in adults and children with asthma and rhinitis. Allergy 1997; 52:971–977.PubMedCrossRefGoogle Scholar
  33. 33.
    In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130–1137.PubMedCrossRefGoogle Scholar
  34. 34.
    Ligget SB. The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 2000; 105(2 pt 2):S487–S492.CrossRefGoogle Scholar
  35. 35.
    Jadad AR, Moher M, Browman GP, Booker L, Sigouin C, Fuentes M, et al. Systematic reviews and meta-analyses on treatment of asthma: critical evaluation. Br Med J 2000; 320:537–540.CrossRefGoogle Scholar
  36. 36.
    Barr RG, Woodruff PG, Clark S, Camargo Jr CA. Sudden-onset asthma exacerbations: clinical features, response to therapy, and 2-week follow-up. Multicenter Airway Research Collaboration (MARC) investigators. Eur Respir J 2000; 15:266–273.PubMedCrossRefGoogle Scholar
  37. 37.
    Salmeron S, Liard R, Elkharrat D, Muir J, Neukirch F, Ellrodt A. Asthma severity and adequacy of management in accident and emergency departments in France: a prospective study. Lancet 2001; 358:629–635.PubMedCrossRefGoogle Scholar
  38. 38.
    Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev 2000; 2: CD000195.PubMedGoogle Scholar
  39. 39.
    Nowak RM, Pensler MI, Sarkar DD, Anderson JA, Kvale PA, Ortiz AE, et al. Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma. Ann Emerg Med 1982; 11:64–69.PubMedCrossRefGoogle Scholar
  40. 40.
    McCarren M, Zalenski RJ, McDermott M, Kaur K. Predicting recovery from acute asthma in an emergency diagnostic and treatment unit. Acad Emerg Med 2000; 7:28–35.PubMedCrossRefGoogle Scholar
  41. 4.
    Milgrom H, Fick Jr RB, Su JQ, Reimann JD, Bush RK, Watrous ML, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-25 Study Group. N Engl J Med 1999; 341:1966–1973.PubMedCrossRefGoogle Scholar
  42. 42.
    Gomez FP, Marrades RM, Iglesia R, Roca J, Barbera JA, Chung KF, et al. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study. Eur Respir J 1999; 14:622–626.PubMedCrossRefGoogle Scholar
  43. 43.
    Snell NJC. Drug interactions with anti-asthma medication. Respir Med 1994; 88:83–88.PubMedCrossRefGoogle Scholar
  44. 44.
    Snell NJC. Adverse reactions to inhaled drugs. Respir Med 1990; 84:345–348.PubMedCrossRefGoogle Scholar
  45. 45.
    Wolff RK. Safety of inhaled proteins for therapeutic use. J Aerosol Med 1998; 11:197–219.PubMedCrossRefGoogle Scholar
  46. 46.
    Weller PF, Plaut M, Taggart V, Trontell A. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108:175–183.PubMedCrossRefGoogle Scholar
  47. 47.
    Ganderton D. General factors influencing drug delivery to the lung. Respir Med 1997; 91:13–16.PubMedCrossRefGoogle Scholar
  48. 48.
    Snell NJC, Ganderton D. Assessing lung deposition of inhaled medications. Consensus statement from a workshop of the British Association for Lung Research. Respir Med 1999; 93:123–133.PubMedCrossRefGoogle Scholar
  49. 49.
    Berg E, Madsen J, Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur Respir J 1998; 12:472–476.PubMedCrossRefGoogle Scholar
  50. 50.
    O’Callaghan C, Barry P. Delivering inhaled corticosteroids to patients. Br Med J 1999; 318:410–411.CrossRefGoogle Scholar
  51. 51.
    Zanen P, Lammers JW. Sample sizes for comparative inhaled corticosteroid trials with emphasis on showing therapeutic equivalence. Eur J Clin Pharmacol 1995; 48:179–184.PubMedCrossRefGoogle Scholar
  52. 52.
    Smyth RL. Research with children. Paediatric practice needs better evidence-gained in collaboration with parents and children. Br Med J 2001; 322:1377–1378.CrossRefGoogle Scholar
  53. 53.
    Smyth RL, Weindling AM. Research in children: ethical and scientific aspects. Lancet 1999; 354 (suppl 2):SII21–SII24.PubMedCrossRefGoogle Scholar
  54. 54.
    Kauffman RE. Clinical trials in children: problems and pitfalls. Paediatr Drugs 2000; 2:411–418.PubMedCrossRefGoogle Scholar
  55. 55.
    McIntosh N, Bates P, Brykczynska G, Dunstan G, Goldman A, Harvey D, et al. Guidelines for the ethical conduct of medical research involving children. Royal College of Paediatrics, Child Health: Ethics Advisory Committee. Arch Dis Child 2000; 82:177–182.PubMedCrossRefGoogle Scholar
  56. 56.
    Burrows B, Barbee RA, Cline MG, Knudson RJ, Lebowitz MD. Characteristics of asthma among elderly adults in a sample of the general population. Chest 1991; 100:935–942.PubMedCrossRefGoogle Scholar
  57. 57.
    Banerjee DK, Lee GS, Malik SK, Daly S. Underdiagnosis of asthma in the elderly. Br J Dis Chest 1987; 81:23–29.PubMedCrossRefGoogle Scholar
  58. 58.
    Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256–1276.PubMedGoogle Scholar
  59. 59.
    Szczelik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999; 104:5–13.CrossRefGoogle Scholar

Copyright information

© Lippincott Williams & Wilkins 2002

Authors and Affiliations

  • Group for the Respect of Ethics and Excellence in Science (GREES): Asthma section
  • S. T. Holgate
    • 1
  • J. Bousquet
    • 2
  • K. F. Chung
    • 3
  • H. Bisgaard
    • 4
  • R. Pauwels
    • 5
  • L. Fabbri
    • 6
  • K. Rabe
    • 7
  • M. Doherty
    • 8
  • N. J. C. Snell
    • 9
  • F. Cuss
    • 10
  • M. D’Amato
    • 11
  • J. Y. Reginster
    • 12
  1. 1.RCMB Division, School of MedicineUniversity of SouthamptonUK
  2. 2.Hôpital Arnaud de VilleneuveMontpellierFrance
  3. 3.Imperial College School of Medicine at the National Heart & Lung InstituteLondonUK
  4. 4.Copenhagen University HospitalDenmark
  5. 5.University HospitalGhentBelgium
  6. 6.University of Modena & ReggioItaly
  7. 7.University Hospital LeidenThe Netherlands
  8. 8.AstraZeneca R&D CharnwoodLoughboroughUK
  9. 9.Bayer PharmaSloughUK
  10. 10.Schering-Plough Research InstituteKenilworthUSA
  11. 11.Rotta Research LaboratoriumMonzaItaly
  12. 12.GREES ASBLLiegeBelgium

Personalised recommendations